**SECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549**

**FORM 10-QSB**

(Mark One)

|  |   | **Quarterly Report pursuant to Section 13      or 15 (d) of the Securities Exchange Act of 1934 for the quarterly period      ended September 30, 2002.** |
|--|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------|

|   |   |                                                                                                                                                                 |
|--------|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|        |   | **Transition Report pursuant to Section 13      or 15 (d) of the Securities Exchange Act of 1934 for the transition period      from ____________ to ____________**. |

Commission File No. 000-30294

**IMX PHARMACEUTICALS, INC.**(Name of Small Business Issuer in its Charter)

| **Utah**        (State or Other Jurisdiction of        Incorporation or Organization)                       |   | **87-0394290**      (I.R.S. Employer Identification Number) |
|-------------------------------------------------------------------------------------------------------------|--------|-------------------------------------------------------------|
|                                                                                                        |   |                                                        |
|                                                                                                        |   |                                                        |
| **Third        Floor, 17 State Street, New York, New York**        (Address of Principal Executive Offices) |   | **10004**      (Zip Code)                                   |

(Issuer’s Telephone Number)  **212.509.9500**

Check whether the issuer (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange  Act of 1934 during the past 12 months (or such shorter period that the registrant was required to file such reports),  and (2) has been subject to such filing requirements for the past 90 days:     Yes  No 

State the number of shares outstanding of each of the issuer’s classes of common equity, as of the latest practicable  date.

At November 13, 2002 there were 10,159,791 shares of common stock, par value $.001 per share outstanding.

Transitional Small Business Disclosure Format (check  one):     Yes   No 

----

**IMX PHARMACEUTICALS, INC. AND SUBSIDIARIES  INDEX**

**PART I - Financial Information**

|                |   |                                                                                                                                                   | PAGENUMBER |   |
|----------------|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------|------------|--------|
| ITEM        1. |   | Financial Statements                                                                                                                                   |       |   |
|                |   |                                                                                                                                                   |       |   |
|                |   | Condensed      Consolidated Balance Sheets as of June 30, 2002 (audited) and September      30, 2002 (unaudited)                                       | 1          |   |
|                |   |                                                                                                                                                   |       |   |
|                |   | Condensed      Consolidated Statements of Operations for the Three Months Ended September      30, 2002 (unaudited) and September 30, 2001 (unaudited) | 2          |   |
|                |   |                                                                                                                                                   |       |   |
|                |   | Condensed      Consolidated Statements of Cash Flows for the Three Months Ended September      30, 2002 (unaudited) and September 30, 2001 (unaudited) | 3          |   |
|                |   |                                                                                                                                                   |       |   |
|                |   | Notes      to Consolidated Financial Statements (unaudited)                                                                                            | 4-13       |   |
|           |   |                                                                                                                                                   |       |   |
| ITEM        2. |        | Management’s      Discussion and Analysis or Plan of Operation                                                                                    | 14-17      |   |
|           |   |                                                                                                                                                   |       |   |
| ITEM        4. |        | Submission      of Matters to a Vote of Security Holders                                                                                               | 18         |   |
|           |   |                                                                                                                                                   |       |   |
| ITEM        5. |        | Resignation      of Director                                                                                                                           | 18         |   |

**PART II - Other Information**

| ITEM        2(a). |        | Changes      in the Rights of Security Holders | 19     |   |
|-------------------|--------|------------------------------------------------|--------|--------|
|              |   |                                           |   |   |
| ITEM        2(c). |        | Recent      Sales of Unregistered Securities   | 19     |   |
|              |   |                                           |   |   |
| ITEM        6.    |        | Exhibits      and Reports on Form 8-K          | 19-20  |   |

----

Back to Contents

**IMX PHARMACEUTICALS, INC. AND SUBSIDIARIES**

**CONDENSED CONSOLIDATED BALANCE SHEET**

|                                                                                                                                                                                                               | **September      30,** |        | **June      30** |   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------|-------------|------------------|--------|
|                                                                                                                                                                                                               | **2002**               |        | **2002**         |   |
|                                                                                                                                                                                                          |                        |             |             |        |  |   |
| ASSETS                                                                                                                                                                                                        | **(Unaudited)**        |        |             |   |   |
| **CURRENT        ASSETS:**                                                                                                                                                                                    |                   |        |             |   |   |   |
| Cash        and cash equivalents                                                                                                                                                                              | $                      | 97,119      |             | $      | 47,320 |   |
| Accounts        receivable, net                                                                                                                                                                               |                   | 411,116     |             |   | 370,802 |   |
| Inventories                                                                                                                                                                                                   |                   | 3,904       |             |   | 7,480 |   |
| Prepaid        expenses and other current assets                                                                                                                                                              |                   | 56,195      |             |   | 53,697 |   |
|                                                                                                                                                                                                          |                        |             |             |        |  |   |
| **Total        Current Assets**                                                                                                                                                                               |                   | 568,334     |             |   | 479,299 |   |
| Property        and Equipment, net                                                                                                                                                                            |                   | 265,158     |             |   | 288,661 |   |
| **OTHER        ASSETS:**                                                                                                                                                                                      |                   |        |             |   |   |   |
| Website        development, net                                                                                                                                                                               |                   | 54,795      |             |   | 71,987 |   |
| Note        receivable                                                                                                                                                                                        |                   | 100,000     |             |   | 100,000 |   |
| Other        assets                                                                                                                                                                                           |                   | 15,457      |             |   | 15,457 |   |
|                                                                                                                                                                                                          |                        |             |             |        |  |   |
| **Total        Other Assets**                                                                                                                                                                                 |                   | 170,252     |             |   | 187,444 |   |
|                                                                                                                                                                                                          |                        |             |             |        |  |   |
| **TOTAL        ASSETS**                                                                                                                                                                                       | $                      | 1,003,744   |             | $      | 955,404 |   |
|                                                                                                                                                                                                          |                        |             |             |        |  |   |
|                                                                                                                                                                                                          |                   |        |             |   |   |   |
| **LIABILITIES        AND STOCKHOLDERS’ DEFICIENCY**                                                                                                                                                      |                   |        |             |   |   |   |
| **CURRENT        LIABILITIES:**                                                                                                                                                                               |                   |        |             |   |   |   |
| Accounts        payable                                                                                                                                                                                       | $                      | 876,664     |             | $      | 952,902 |   |
| Notes        and obligations payable, current portion                                                                                                                                                         |                   | 400,000     |             |   | 599,463 |   |
| Accrued        expenses                                                                                                                                                                                       |                   | 1,086,784   |             |   | 1,068,315 |   |
| Due        to related parties                                                                                                                                                                                 |                   | 268,750     |             |   | 408,750 |   |
| Deferred        revenues                                                                                                                                                                                      |                   | 422,198     |             |   | 412,558 |   |
| Other        current liabilities                                                                                                                                                                              |                   | 76,332      |             |   | 25,663 |   |
|                                                                                                                                                                                                          |                        |             |             |        |  |   |
| **Total        Current Liabilities**                                                                                                                                                                          |                   | 3,130,728   |             |   | 3,467,651 |   |
| **NOTES        AND OBLIGATIONS PAYBLE, NET OF CURRENT PORTION**                                                                                                                                               |                   | 2,143,070   |             |   | 1,075,000 |   |
| **STOCKHOLDERS’        DEFICIENCY:**                                                                                                                                                                     |                   |        |             |   |   |   |
| Preferred        stock, $.001 par value; 1,000,000 shares authorized Class B convertible        preferred stock, $80.00 stated value,        350,000 shares authorized; 223,820 shares issued and outstanding |                   | 224,800     |             |   | 224,800 |   |
| Common        stock, $.001 par value; 50,000,000 shares authorized; 9,248,113 shares        issued and 9,024,791 shares outstanding                                                                           |                   | 9,248       |             |   | 9,248 |   |
| Additional        paid-in capital                                                                                                                                                                             |                   | 13,199,553  |             |   | 13,199,553 |   |
| Accumulated        deficit                                                                                                                                                                                    |                   | (17,027,730 | )                |   | (16,347,789 | ) |
| Cumulative        translation adjustment                                                                                                                                                                      |                   | (99,671     | )                |   | (96,805 | ) |
| Less:        Treasury Stock, at cost                                                                                                                                                                          |                   | (576,254    | )                |   | (576,254 | ) |
|                                                                                                                                                                                                          |                        |             |             |        |  |   |
| **Total        Stockholders’ Deficiency**                                                                                                                                                                |                   | (4,270,054  | )                |   | (3,587,247 | ) |
|                                                                                                                                                                                                          |                        |             |             |        |  |   |
| **TOTAL        LIABILITIES AND STOCKHOLDERS’ DEFICIENCY**                                                                                                                                                | $                      | 1,003,744   |             | $      | 955,404 |   |
|                                                                                                                                                                                                          |                        |             |             |        |  |   |

The accompanying notes are an integral  part of these financial statements.

- 1 -

----

Back to Contents

**IMX PHARMACEUTICALS, INC. AND SUBSIDIARIES**

**CONDENSED CONSOLIDATED STATEMENTS  OF OPERATIONS AND COMPREHENSIVE LOSS  FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2002 AND 2001  (Unaudited)**

|                                                                   | **2002** |      | **2001** |   |
|-------------------------------------------------------------------|----------|-----------|----------|--------|
|                                                              |          |           |     |        |  |   |
| **REVENUES**                                                      | $        | 1,236,783 |     | $      | 846,373 |   |
| **COST        OF REVENUES**                                       |     | 653,086   |     |   | 423,529 |   |
|                                                              |          |           |     |        |  |   |
| **GROSS        PROFIT**                                           |     | 583,697   |     |   | 422,844 |   |
|                                                              |          |           |     |        |  |   |
| **COSTS        AND EXPENSES:**                                    |     |      |     |   |   |   |
| Sales        and marketing                                        |     | 197,445   |     |   | 327,890 |   |
| Payroll        and payroll related expenses                       |     | 493,146   |     |   | 693,020 |   |
| Depreciation        and amortization                              |     | 42,992    |     |   | 102,756 |   |
| Loss        on website development impairment                     |     | —    |     |   | 116,103 |   |
| Loss        on fixed asset impairment                             |     | —    |     |   | 139,568 |   |
| Loss        on goodwill impairment                                |     | —    |     |   | 600,311 |   |
| Other        operating expenses                                   |     | 508,920   |     |   | 364,094 |   |
|                                                              |          |           |     |        |  |   |
| **Total        Costs and Expenses**                               |     | 1,242,503 |     |   | 2,343,742 |   |
| **LOSS        FROM OPERATIONS**                                   |     | (658,806  | )        |   | (1,920,898 | ) |
| **OTHER        INCOME (EXPENSES):**                               |     |      |     |   |   |   |
| Interest        expense                                           |     | (26,627   | )        |   | (937 | ) |
| Other        income (expense)                                     |     | 5,492     |     |   | (14,974 | ) |
|                                                              |     |      |     |   |   |   |
|                                                              |          |           |     |        |  |   |
| **Total        Other Income (Expenses)**                          |     | (21,135   | )        |   | (15,911 | ) |
| **NET        LOSS**                                               |     | (679,941  | )        |   | (1,936,809 | ) |
|                                                              |          |           |     |        |  |   |
| **OTHER        COMPREHENSIVE LOSS:**                              |     |      |     |   |   |   |
| Foreign        currency translation adjustments                   |     | (2,866    | )        |   | (15,222 | ) |
|                                                              |          |           |     |        |  |   |
| **TOTAL        COMPREHENSIVE LOSS**                               | $        | (682,807  | )        | $      | (1,952,031 | ) |
|                                                              |          |           |     |        |  |   |
| **NET        LOSS PER SHARE, BASIC AND DILUTED**                  | $        | (0.08     | )        | $      | — |   |
|                                                              |          |           |     |        |  |   |
| **NET        LOSS PER SHARE, BASIC AND DILUTED – PRO FORMA** | $        | —    |     | $      | (0.21 | ) |
|                                                              |          |           |     |        |  |   |
| **WEIGHTED        AVERAGE NUMBER OF COMMON SHARES OUTSTANDING**   |     | 9,024,791 |     |   | 9,024,791 |   |
|                                                              |          |           |     |        |  |   |

The accompanying notes are an integral part of these financial statements.

- 2 -

----

Back to Contents

**IMX PHARMACEUTICALS, INC. AND SUBSIDIARIES**

**CONDENSED CONSOLIDATED STATEMENTS  OF CASH FLOWS  FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2002 AND 2001  (Unaudited)**

|                                                                                        | **2002** |      | **2001** |   |
|----------------------------------------------------------------------------------------|----------|-----------|----------|--------|
|                                                                                   |          |           |     |        |  |   |
| **CASH        FLOWS FROM OPERATING ACTIVITIES:**                                       |     |      |     |   |   |   |
| Net        loss                                                                        | $        | (679,941  | )        | $      | (1,936,809 | ) |
| Adjustments        to reconcile net loss to net cash provided by operating activities: |     |      |     |   |   |   |
| Loss        on fixed asset impairment                                                  |     | —    |     |   | 139,568 |   |
| Loss        on website development                                                     |     | —    |     |   | 116,103 |   |
| Loss        on goodwill impairment                                                     |     | —    |     |   | 600,311 |   |
| Depreciation        and amortization                                                   |     | 42,992    |     |   | 102,756 |   |
| Changes        in operating assets and liabilities:                                    |     |      |     |   |   |   |
| Accounts        receivable                                                             |     | (40,314   | )        |   | (182,741 | ) |
| Prepaid        and other current assets                                                |     | (2,498    | )        |   | (22,299 | ) |
| Inventories                                                                            |     | 3,576     |     |   |   |   |
| Accounts        payable and accrued expenses                                           |     | (57,769   | )        |   | 432,434 |   |
| Current        liabilities – Due to related parties                               |     | 60,000    |     |   | — |   |
| Other        current liabilities                                                       |     | 50,669    |     |   | 32,831 |   |
| Deferred        revenues                                                               |     | 9,640     |     |   | 31,642 |   |
|                                                                                   |          |           |     |        |  |   |
| **Net        Cash Used in Operating Activities**                                       |     | (613,645  | )        |   | (686,204 | ) |
|                                                                                   |          |           |     |        |  |   |
| **CASH        FLOWS FROM INVESTING ACTIVITIES:**                                       |     |      |     |   |   |   |
| Purchase        of property and equipment                                              |     | (2,297    | )        |   | (9,815 | ) |
|                                                                                   |          |           |     |        |  |   |
| **Net        Cash Used in Investing Activities**                                       |     | (2,297    | )        |   | (9,815 | ) |
|                                                                                   |          |           |     |        |  |   |
| **CASH        FLOWS FROM FINANCING ACTIVITIES:**                                       |     |      |     |   |   |   |
| Proceeds        from loans from related parties                                        |     | 1,068,070 |     |   | — |   |
| Repayment        of debt                                                               |     | (399,463  | )        |   | (3,169 | ) |
|                                                                                   |          |           |     |        |  |   |
| **Net        Cash Provided by (Used in) Financing Activities**                         |     | 668,607   |     |   | (3,169 | ) |
|                                                                                   |          |           |     |        |  |   |
| Effect        of exchange rate changes on cash                                         |     | (2,866    | )        |   | 222 |   |
| Increase        (decrease) in cash and cash equivalents                                |     | 49,799    |     |   | (698,966 | ) |
| **Cash        and cash equivalents, beginning of year**                                |     | 47,320    |     |   | 738,216 |   |
|                                                                                   |          |           |     |        |  |   |
| **Cash        and cash equivalents, September 30,**                                    | $        | 97,119    |     | $      | 39,250 |   |
|                                                                                   |          |           |     |        |  |   |
| **SUPPLEMENTAL        DISCLOSURE OF CASH FLOW INFORMATION**                            |     |      |     |   |   |   |
| Cash        paid for interest                                                          | $        | —    |     | $      | — |   |
|                                                                                   |          |           |     |        |  |   |
| Cash        paid for income taxes                                                      | $        | —    |     | $      | — |   |
|                                                                                   |          |           |     |        |  |   |

The accompanying notes are an integral part of these financial statements.

- 3 -

----

Back to Contents

**IMX PHARMACEUTICALS, INC. AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED  FINANCIAL STATEMENTS  SEPTEMBER 30, 2002  (Unaudited)**

**NOTE 1 – BASIS OF PRESENTATION**

     The condensed consolidated balance sheet as of September 30, 2002, the condensed consolidated statements of  operations for the three months ended September 30, 2002 and 2001, and the condensed consolidated statements of  cash flows for the three months ended September 30, 2002 and 2001 are unaudited. However, in the opinion of  management, all adjustments (which include reclassifications and normal recurring adjustments) necessary to present  fairly the financial position, results of operations and cash flows at September 30, 2002 and for all periods presented,  have been made. The results of operations for the three-month period ended September 30, 2002 are not necessarily  indicative of the operating results for the full year.

     These condensed consolidated financial statements and notes are presented in accordance with rules and  regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally  included in the consolidated financial statements prepared in accordance with accounting principles generally  accepted in the United States of America have been condensed or omitted. It is suggested that these condensed  consolidated financial statements be read in conjunction with the Company’s consolidated financial statements and  notes thereto included in the Company’s June 30, 2002 Form 10-KSB.

**Principles of Consolidation**

     The condensed consolidated financial statements include the accounts of the Company and its wholly-owned  subsidiaries, Findstar, plc, (“Findstar”), ThinkDirectMarketing, Inc. (“TDMI”), TDMI’s wholly-owned subsidiary,  DirectMailQuotes, LLC (“DMQ”), and Findstar’s wholly-owned subsidiaries, Panda Software (UK) Limited and Blue Van  Limited (formerly Panda Antivirus Software Limited). All significant intercompany balances and transactions have  been eliminated.

**Reporting Period**

     As further explained in Note 3, the acquisition of Findstar and TDMI in December 2001 was accounted for as a  capital transaction, in a reverse acquisition and recapitalization. No goodwill or other intangible assets were recorded.  Both Findstar and TDMI were deemed to be the accounting acquirers and the Company was deemed the legal  acquirer. The accompanying condensed consolidated financial statements for the three months ended September 30,  2002

- 4 -

----

Back to Contents

**IMX PHARMACEUTICALS, INC. AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED  FINANCIAL STATEMENTS  SEPTEMBER 30, 2002  (Unaudited)**

**NOTE 1 – BASIS OF PRESENTATION (CONTINUED)**

depict the results of operations of the Company and its wholly-owned subsidiaries. The accompanying condensed  consolidated financial statements for the three months ended September 30, 2001 depict the results of operations of  Findstar and TDMI and their wholly owned subsidiaries only.

**NOTE 2 – BANKRUPTCY AND REORGANIZATION**

     On November 20, 2000 the Company and its wholly-owned subsidiary, imx-eti LifePartners, Inc. (“imx-eti”) filed  voluntary petitions for relief under Chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy  Court for the Southern District of Florida, West Palm Beach Division. On December 27, 2000, the Bankruptcy Court  ordered the joint administration of the two cases.

     On August 10, 2001, the Company filed its Third Amended Plan of Reorganization (the “Plan”). The Plan provided  that all administrative expenses, priority tax claims and US Trustee’s fees would be paid in full. The Plan also  provided for nine Classes of Claims, each treated in its own way.

     On September 26, 2001, after a hearing, the Court confirmed the Plan. The order was entered on October 11,  2001. The Plan was declared effective on December 11, 2001.

     On December 11, 2001, the effective date of the Plan of Reorganization, all 8,132,076 shares of Common Stock  presently outstanding were automatically reversed on the basis of one share for each 20 presently held (reverse split).  Any fractional shares were rounded up to the next full share. After the reverse split, there were 421,850 shares  outstanding that were derived from the previously outstanding common stock.

     In addition, all unsecured and allowed claims were settled on the basis of one share for every four ($4.00) dollars  of allowed claim. Any fractional shares were rounded up to the next full share. Approximately 842,594 shares were or  will be issued to Class 5, 6, 7, and 8 creditors. The reverse split and the issuance of the common stock to creditors are  exempt from the registration requirements of Section 5 of the Securities Act pursuant to section 1145 of the United  States Bankruptcy Act.

- 5 -

----

Back to Contents

**IMX PHARMACEUTICALS, INC. AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED  FINANCIAL STATEMENTS  SEPTEMBER 30, 2002  (Unaudited)**

**NOTE 2 – BANKRUPTCY AND REORGANIZATION (CONTINUED)**

     While the bankruptcy  case was pending, imx-eti and the Company’s other subsidiaries, Sarah J,  Inc. (d/b/a Mother 2 BeTM), ProctozoneTM, Inc., PodiatrxTM, Inc., and  IMX Select Benefits Corporation (which were never parties to the bankruptcy  proceedings) maintained minor activity.

     All of the Company’s operations were conducted through its subsidiaries. All of the Company’s pharmaceutical  and direct marketing subsidiaries were sold on December 11, 2001; The losses resulting from these subsidiaries were closed to additional paid-in capital pursuant to Generally Accepted Accounting Principles “fresh start accounting” rules on December 31, 2001.

**NOTE 3 – ACQUISITIONS**

**Acquisitions of Findstar and TDMI**

     On September 30, 2001, the Company, as purchaser, entered into an agreement (the “Purchase Agreement”) with  Cater Barnard plc, f/k/a VoyagerIT.com (“Cater Barnard”) and Envesta plc (“Envesta”), as sellers for the acquisitions of  TDMI and Findstar.

     Pursuant to the Purchase Agreement, the Company acquired Findstar and 17.5% of the equity of TDMI in  December 2001, with the remaining equity interest of TDMI acquired in January 2002.

     As a result of the Company having disposedof all of its prior subsidiaries, the Company had minimal net assetsprior to this acquisition. In addition, since Cater Barnard and Evesta would holdapproximately 86% of the equity of  the Company after the acquisition, assuming conversionof the Class B Preferred Stock and the Warrant issued as part  of the acquisition price, theCompany accounted for the acquisition as a capital transaction, in a reverse acquisitionand recapitalization. No goodwill or other intangible assets were recorded. Both Findstarand TDMI were deemed to  be the accounting acquirers and the Company wasdeemed the legal acquirer.

**NOTE 4 – GOING CONCERN CONSIDERATIONS**

The accompanying condensed consolidated financial statements have beenpresented assuming the continuity of the Company as a going concern. However,the Company has incurred

- 6 -

----

Back to Contents

**IMX PHARMACEUTICALS, INC. AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED  FINANCIAL STATEMENTS  SEPTEMBER 30, 2002  (Unaudited)**

**NOTE 4 – GOING CONCERN CONSIDERATIONS (CONTINUED)**

substantial losses resulting in an accumulated deficit of $16,997,730 as of September 30, 2002 after a fresh start  accounting effective December 31, 2001. These conditions raise substantial doubt as to the ability of the Company to  continue as a going concern.

| Management’s plans with regards to this issue are as follows: |
|--------------------------------------------------------------------|
|                                                               |

| • |   | To raise capital in the public market as needed,      and     |
|--------|--------|---------------------------------------------------------------|
|   |   |                                                          |
| • |   | To seek additional loans from its existing      shareholders. |

     Presently, the Company cannot ascertain the eventual success of management’s plans with any degree of  certainty. The accompanying consolidated financial statements do not include any adjustments that might result from  the eventual outcome of the risks and uncertainty described above.

**NOTE 5 – FIXED ASSETS IMPAIRMENT**

     During the quarter ended September 30, 2001, management determined that the fair value of certain computers and other equipment were less than their current book value. Accordingly, the Company recorded asset impairments of $139,568.

**NOTE 6 – WEBSITE DEVELOPMENT IMPAIRMENT**

     During the quarter ended September 30, 2001, the Company determined that the carrying amount of its website exceeded its fair value by approximately $116,000. Accordingly, an impairment loss of that amount was recognized and included in the condensed consolidated statement of operations.

**NOTE 7 – GOODWILL IMPAIRMENT**

     During the quarter ended September 30, 2001, management determined that the carrying amount of goodwill  associated with the acquisition of DMQ by TDMI was impaired. Accordingly, the Company recorded a loss of $600,311  on goodwill impairment.

- 7 -

----

Back to Contents

**IMX PHARMACEUTICALS, INC. AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED  FINANCIAL STATEMENTS  SEPTEMBER 30, 2002  (Unaudited)**

**NOTE 8 – NOTE RECEIVABLE**

     On December 11, 2001, the Company and Shalom Y’all, Inc. (“Shalom”), a company wholly-owned by William A.  Forster, the Company’s former Chairman and CEO, executed a settlement agreement that provided for the deferred  payment of Mr. Forster’s secured claim, the settlement and payment of his administrative claim, the sale to Shalom of  the Company’s subsidiaries, and the indemnification of the Company for any claims against it arising from the  operation of the subsidiaries’ businesses.

     The purchase price for the subsidiaries was $100,000. The obligation to make this payment is evidenced by a  promissory note issued by Shalom Y’all, Inc.’s payable in three years. The note is secured by the pledge of 25,000  shares of Mr. Forster’s Common Stock.

**NOTE 9 – DUE TO RELATED PARTIES**

     At September 30, 2002, the Company owed $268,750 to Cater Barnard USA, a company owned by Cater Barnard,  for office facilities and other services performed on behalf of the Company.

     In addition, at June 30, 2002, the Company was indebted in the amount of $200,000 to Envesta, plc, a Company  in which Cater Barnard has an 86% interest in, in connection with the Company acquiring from Envesta debts owed to  Envesta by Findstar. The $200,000 was paid during the quarter ended September 30, 2002.

**NOTE 10 – NOTES PAYABLE**

     Notes payable consisted of the following as of September 30, 2002 and June 30, 2002, respectively:

- 8 -

----

Back to Contents

**IMX PHARMACEUTICALS, INC. AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED  FINANCIAL STATEMENTS  SEPTEMBER 30, 2002  (Unaudited)**

**NOTE 10 – NOTES PAYABLE (CONTINUED)**

|                                                          | **September 30,** |      | **June 30,** |   |
|----------------------------------------------------------|-------------------|-----------|--------------|--------|
|                                                          | **2002**          |      | **2002**     |   |
|                                                     |                   |           |         |        |  |   |
|                                                          | **(Unaudited)**   |      |         |   |   |
| Notes payable to Cater Barnard, plc,                     | $                 | 2,143,070 |         | $      | 1,075,000 |   |
| Note payable to William Forster                          |              | —    |         |   | 27,463 |   |
| Note payable to Axciom Corporation due in February, 2003 |              | 400,000   |         |   | 400,000 |   |
| Note payable to William Spero                            |              | —    |         |   | 172,000 |   |
|                                                     |                   |           |         |        |  |   |
| Total                                                    | $                 | 2,543,070 |         | $      | 1,674,463 |   |
|                                                     |                   |           |         |        |  |   |

**Notes Payable to Cater Barnard**

     During the year ended June 30, 2002, TDMI, Findstar and IMX borrowed $1,120,427 from Cater Barnard. The  Company agreed to convert $120,427 of this balance into 240,854 shares of its Common Stock. The transaction has  been reflected as of June 30, 2002. On June 27, 2002, the remaining balance of $1,000,000, along with accrued interest  of $75,000 due on all of the Cater Barnard notes, was converted into a $1,075,000 note due July 1, 2004. The note  bears interest at 5% per annum until June 30, 2003, and 7.8% thereafter. Accrued interest on the note as of September  30, 2002 amounted to $13,437.

     During the quarter ended September 30, 2002, the Company borrowed $750,010 from Cater Barnard. The note  evidencing the loan bears interest at 7.8% per annum and matures on August 1, 2004. It is convertible into 4 shares of  IMX Common Stock for every dollar of principal and accrued interest. The note is secured by the equity in and debt  from the Company’s subsidiaries. Accrued interest on this note amounted to $9,841 at September 30, 2002.

     During the quarter ended September 30, 2002, the Company borrowed $311,060 from Cater Barnard. The note  bears interest at 5% per annum until August 31, 2003, and 7.8% per

- 9 -

----

Back to Contents

**IMX PHARMACEUTICALS, INC. AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED  FINANCIAL STATEMENTS  SEPTEMBER 30, 2002  (Unaudited)**

**NOTE 10 – NOTES PAYABLE (CONTINUED)**

**Notes Payable to Carter Barnard (Continued)**

annum thereafter, and matures on September 1, 2004. Accrued interest on this note amounted to $1,296 at September  30, 2002.

**Note Payable to William Forster**

     On December 11, 2001, the Company and Shalom Y’all executed and consummated an agreement providing for  the deferred payment of Mr. Forster’s secured claim of $67,000, the settlement and payment of his administrative  claim, and for the sale to Shalom Y’all of all of the Company’s subsidiaries, and its indemnification of the Company  for any claims against it arising from the operation of the subsidiaries’ businesses (Note 8).

     The agreement provided for a payment of $50,000 to induce Shalom Y’all to provide the indemnity. $35,000 of  the indemnity amount was paid at closing. The balance, together with the $67,000 secured claim, is evidenced by a  promissory note issued by the Company in the amount of $82,000. The note was due on February 28, 2002 and bears  interest at the rate of 15% per annum, from December 11, 2001. On March 20, 2002 the note was re-cast to provide for  the periodic payments of principal and interest to be paid from December 11, 2001. At that time, a partial principal  payment of $25,000 was made and the unpaid interest of $3,333 was added to the principal of the note. Additional  payments totaling $35,000 were made. On June 28, 2002, the Company issued a replacement note in the principal  amount of $27,463, consisting of $22,000 of principal and $5,463 of unpaid interest. The note was paid during the  quarter ended September 30, 2002.

**Note Payable to Axciom Corporation**

     As of June 30, 2002, the Company was obligated on a note payable to Axciom Corporation in the amount of  $400,000 that was due on December 31, 2001. The maturity of the note was extended to February 2003.

**Note Payable to William Spero**

     As of June 30, 2002, TDMI was indebted to William Spero, DMQ’s former principal owner, in the amount of  $114,000 plus accrued interest, as part of the acquisition of DMQ by TDMI.

- 10 -

----

Back to Contents

**IMX PHARMACEUTICALS, INC. AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED  FINANCIAL STATEMENTS  SEPTEMBER 30, 2002  (Unaudited)**

**NOTE 10 – NOTES PAYABLE (CONTINUED)**

**Note Payable to William Spero (Continued)**

     TDMI had defaulted under the note and several subsequent settlement agreements. On August 13, 2002, the  Company entered into an agreement with Mr. Spero whereby the Company agreed to pay $172,000 to settle the note,  reclaim property to which Mr. Spero was entitled as the result of the prior defaults, and pay his legal costs during the  default period. Interest expense of $58,000 was recognized during the year ended June 30, 2002. The note was paid  during the quarter ended September 30, 2002.

     Maturities of long-term debt at September 30, 2002 consisted of the following:

| 2003                  | $      | 400,000   |   |
|-----------------------|--------|-----------|--------|
| 2004                  |   | 2,143,070 |   |
|                  |        |           |   |
| Total                 |   | 2,543,070 |   |
| Less: Current Portion |   | (400,000  | )      |
|                  |        |           |   |
|                       | $      | 2,143,070 |   |
|                  |        |           |   |

**NOTE 11 – EQUITY**

**Shares Issued and to be Issued to Creditors in Bankruptcy Settlements**

     Pursuant to the Plan of Reorganization, all unsecured allowed claims were to be settled on the basis of one share  for every $4.00 of allowed claim, with any fractional shares to be rounded up to the next full share. Per the Plan, a  total of 842,594 shares were to be issued to class 5, 6, 7 and 8 creditors. As of September 30, 2002, a total of 731,074  shares have been issued, resulting in a credit to equity of $2,924,296. The remaining 111,520 shares, valued at  $446,080, have not been issued, but are included in equity as of September 30, 2002 as a credit to additional paid-in  capital.

**Modification of Class B Preferred Stock**

     As of June 30, 2002, the Company had $544,377 of dividends in arrears related to the Series B Preferred Stock.  However, the provision for payment or accumulation of dividends on the Series B Preferred Stock, payable in cash or  Common Stock, at the Company’s election, was subsequently eliminated. Furthermore, the number

- 11 -

----

Back to Contents

**IMX PHARMACEUTICALS, INC. AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED  FINANCIAL STATEMENTS  SEPTEMBER 30, 2002  (Unaudited)**

**NOTE 11 – EQUITY (CONTINUED)**

**Modification of Class B Preferred Stock (Continued)**

of shares of Common Stock to be issued upon conversion of each Preferred share doubled to 40 instead of 20 as  previously provided. This was accomplished by reducing the conversion price to $2.00 per share of Common Stock.

**NOTE 12 – SEGMENT DISCLOSURES**

     The Company’s reportable operating segments include Findstar and its subsidiaries, Panda Software (UK)  Limited and Blue Van Limited and TDMI and its subsidiary, DMQ. Findstar’s business consists of the distribution of  anti-virus software known as Panda Software, one of the United Kingdom’s leading anti-virus software systems. The  Panda Software is also distributed outside the United Kingdom. TDMI designs, develops and distributes products and  services that automate and streamline direct marketing and customer relationship management processes. DMQ, is an  online market place for sellers of direct mail, providing leads, website applications, mailing lists, mailing supplies as  well as other products and services.

     The Company allocates the costs of revenues and direct operating expenses to these segments.

     Operating segments for the quarter ended September 30, 2002 and 2001 were as follows:

     Quarter ended September 30, 2002:

|                               | **Findstar** |     | **TDMI/DMQ** |   | **Corporate** |   | **Total** |    |
|-------------------------------|--------------|----------|--------------|--------|---------------|--------|-----------|---------|
|                          |              |          |         |        |               |   |           |         |   |  |  |   |
| Revenues                      | $            | 275,371  |         | $      | 961,412       |   | $         | —  |   | $ | 1,236,783 |   |
| Cost of revenues              |         | (101,730 | )            |   | (551,356      | )      |      | —  |   |   | (653,086 | ) |
|                          |              |          |         |        |               |   |           |         |   |  |  |   |
| Gross profit                  | $            | 173,641  |         | $      | 410,056       |   | $         | —  |   | $ | 583,697 |   |
|                          |              |          |         |        |               |   |           |         |   |  |  |   |
| Depreciation and amortization | $            | 3,897    |         | $      | 39,095        |   | $         | —  |   | $ | 42,992 |   |
|                          |              |          |         |        |               |   |           |         |   |  |  |   |
| Total assets                  | $            | 283,912  |         | $      | 607,094       |   | $         | 112,738 |   | $ | 1,003,744 |   |
|                          |              |          |         |        |               |   |           |         |   |  |  |   |
| Capital expenditures          | $            | —   |         | $      | 2,297         |   | $         | —  |   | $ | 2,297 |   |
|                          |              |          |         |        |               |   |           |         |   |  |  |   |

- 12 -

----

Back to Contents

**IMX PHARMACEUTICALS, INC. AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED  FINANCIAL STATEMENTS  SEPTEMBER 30, 2002  (Unaudited)**

**NOTE 12 – SEGMENT DISCLOSURES (CONTINUED)**

**Quarter ended September 30, 2001:**

|                               | **Findstar** |      | **TDMI/DMQ** |   | **Corporate** |   | **Total** |      |
|-------------------------------|--------------|-----------|--------------|--------|---------------|--------|-----------|-----------|
|                          |              |           |         |        |               |   |           |           |   |  |  |   |
| Revenues                      | $            | 322,064   |         | $      | 524,309       |   | $         | —    |   | $ | 846,373 |   |
| Cost of revenues              |         | (121,604  | )            |   | (301,925      | )      |      | —    |   |   | (423,529 | ) |
|                          |              |           |         |        |               |   |           |           |   |  |  |   |
| Gross profit                  | $            | 200,460   |         | $      | 222,384       |   | $         | —    |   | $ | 422,844 |   |
|                          |              |           |         |        |               |   |           |           |   |  |  |   |
| Depreciation and amortization | $            | 24,114    |         | $      | 78,642        |   | $         | —    |   | $ | 102,756 |   |
|                          |              |           |         |        |               |   |           |           |   |  |  |   |
| Total assets                  | $            | 1,561,751 |         | $      | 712,890       |   | $         | 1,622,016 |   | $ | 3,896,657 |   |
|                          |              |           |         |        |               |   |           |           |   |  |  |   |
| Capital expenditures          | $            | —    |         | $      | 9,815         |   | $         | —    |   | $ | 9,815 |   |
|                          |              |           |         |        |               |   |           |           |   |  |  |   |

**NOTE 13 – PENDING ACQUISITION**

     On August 28, 2002, the Company signed a letter of intent to acquire 100% of the Common Stock of Healthcare  Dialog, Inc. (“HDI”). The purchase price of the acquisition will be paid through the issuance of IMX Common Stock. It  is expected that, after closing, the current shareholders of HDI will own 50% of the company.

     On November 7, 2002,  the Board of Directors and HDI reached a definitive agreement to merge the Company  and HDI. The merger will be on an approximate one on one basis. The merger is  subject to obtaining sufficient financing. The Company will file the required  audited and pro-forma financial statements within seventy five days after the  merger is consummated.

- 13 -

----

Back to Contents

**Item 2.**     **Management’s Discussion and Analysis or Plan of Operation.**

*General*

     IMX Pharmaceuticals, Inc. (the “Company”) is a technology driven marketing and sales solution Company that  provides direct mail and telemarketing services through its wholly owned subsidiaries ThinkDirectMarketing, Inc.  (TDMI) and Findstar, plc. In August 2002 the Company signed a letter of intent to acquire Healthcare Dialog, Inc., a  leading provider of relationship marketing communications services to the healthcare industry, and certain related  companies. A definitive agreement was completed in November 2002. The closing, planned for around the year’s end,  is subject, among other things, to the conclusion of certain Company financings. The merged company will operate  under the new name, Dialog Group.

     During December 2001, the Company emerged from reorganization and its old operations and businesses were  exited and/or disposed. The Company subsequently acquired Think Direct Marketing, Inc (“TDMI”) and Findstar, PLC  (“Findstar”).

*Description of TDMI and Findstar*

     TDMI is a US company that provides businesses the ability to target, create, print and execute a direct marketing  campaign online from their desktop computer. TDMI offers online subscribers access to consumer and business  databases containing opt-in information on over 100 million US consumers that can be searched both geographically,  demographically, income, and other personal profiles. In addition to its subscription products TDMI offers thousands  of specialized consumer lists from the nations largest data compilers including Acxiom, Inc, InfoUSA and Equifax. To  complement these data services TDMI has made available to its customers the ability to use its online mailing  solutions to execute direct mail campaigns from the desktop.

     TDMI Partners include: United States Postal Service (which has access to approximately 250 million households  and 16 million businesses); Microsoft, a worldwide leader in software, services and Internet technologies for personal  and business computing; Avery Dennison, a global leader in label & office products; Acxiom, one of the leading  aggregators of direct marketing lists in the world; Claritas, a leading provider of marketing information solutions,  including marketing databases, industry-expertise, data access and analysis; U.S.A. Direct, a provider of direct mail  production services including design, printing, inserts; National Association of Insurance and Financial Advisors  (NAIFA) consisting of approximately 70,000 insurance and financial advisors worldwide; National Restaurant  Association, the leading business association for the restaurant industry, comprised of 858,000 restaurants; Artisoft, a  provider of computer telephony systems; and Interactive Intelligence, a developer of enterprise software for call  centers.

     TDMI’s direct  mail, mailing services, and telemarketing products are specifically tailored  to provide a cost- effective and powerful direct marketing solution for new

- 14 -

----

Back to Contents

customer acquisition and customer retention to  the more than 20 million small and medium size businesses in the United States.  Products and services are delivered from the Company’s web site and sales  offices in the U.S. In addition, the Company is a frequent speaker at the United  States Postal Services “Direct Mail Made Easy” seminar series. The  Company presented at more than 40 seminars in the first 9 months of 2002.

     In April 2001, TDMI  completed the acquisition of DirectMailQuotes, LLC (“DMQ”) to further  expand into direct product sales to the letter shop channel. DMQ through its  MailMogul professional brand, provides mailing list acquisition, mailing supplies,  National Change of Address (NCOA) for data cleansing and enhancement and the  industries premier lead generation service, Directmailquotes.com, for the letter  shop channel. As DMQ was also one of the five USPS partners, the acquisition  consolidated TDMI’s position as the Postal Services leading affiliate.

     Findstar plc is a sales led organization with telemarketing capabilities currently selling and distributing on an  exclusive basis the Panda Software anti-virus software and products in the UK.

     Panda UK holds the exclusive distribution license for the sale, marketing, and distribution of Panda Software  products through out England, as well as in Scotland and Wales. The licence has a five-year term ending in January  2006, with an option for an additional two years. The license may be renewed for additional periods.

     Panda UK was established in 1999 to acquire the exclusive licence for Panda Software products. Panda Antivirus  was established in 1999 as a reseller of Panda Software products under an arrangement with Panda UK. Findstar was  incorporated in January 2001 as the holding company for Panda UK and Panda Antivirus.

*Results of Operations*

     The Company’s operations reflected in this quarter’s financial statements include both its Findstar and TDMI  subsidiaries. The Company’s pharmaceutical and direct marketing subsidiaries were sold during the last quarter of  2001 and are not included in the financial statements because their operations were discontinued. The losses resulting  from these subsidiaries were netted against additional paid in capital in a fresh start accounting on December 31,  2001.

     *TDMI*:

     For the three months ended September 30, 2002, TDMI’s consolidated net sales (including DMQ) were  approximately $961,000 as compared to approximately $524,000 for the same period ended September 30, 2001, an  increase of about $437,000 or more than 80%. The improved results are due to 1) the continued growth of the data  and service product lines in the small and medium business area, and 2) growth in new customer re-orders and  renewals in the letter shop channel and 3) new customer acquisition and retention for the DigitalData call center  services products. During this

- 15 -

----

Back to Contents

period TDMI recorded record unit sales for its data subscription products and specialty lists services.

     TDMI’s gross margin on sales for the third quarter of 2002 was almost 43%, approximately the same during this  quarter in 2001.

     TDMI’s consolidated total operating expenses were approximately $860,000 for the three months ended  September 30, 2002. This compares with approximately $2,041,000 for the same period ended September 30, 2001.  The decrease between periods, year to year, at a time of greatly increased overall sales was accomplished by 1) the  reduction of advertising and marketing expenses as the channel sales programs generated significantly more qualified  sales prospects for our sales team and web sites and 2) customer reorders reduced acquisition costs. At the same  time, with the completion of several product development efforts and consolidation of operations with DMQ, we have  been able to reduce our administrative costs.

     For the three months ended September 30, 2002, TDMI’s consolidated net loss from operations was  approximately $(450,000). This represents an improvement from net losses of about $(1,819,000) in the period ending  September 30, 2001. Increased sales during this period combined with reduced marketing and administrative  expenses combined to improve the bottom line. The decrease in net loss is also partly due to the non-recurrence of a  $600,000 loss on goodwill impairment, a $116,000 loss on website impairment, and a $140,000 loss on fixed assets  impairment during 2001.

     This was TDMI’s sixth consecutive quarter of improved performance, including gains in sales, reduction in  operating expenses, and improvement in gross profit.

     *Findstar*:

     For the three months  ended September 30, 2002, the Findstar’s consolidated net sales were approximately  $275,000, as compared to $322,000 for the same period ended September 30, 2001.  This decrease is due to a decrease in completed sales transactions. Also, the  2001 figures included two unusually large transactions totaling around $117,000.

     The Findstar’s  gross profit margin for the three months ended September 30, 2002 were both  approximately 63%. The margins for the three months to September 30, 2001 approximately  62%.

     The Findstar’s total operating expenses were approximately $287,000 for the three months ended September 30,  2002. Operating expenses for same period to September 30, 2001 were approximately $303,000 respectively.

     For the three months months ended September 30, 2002, the Findstar’s net (loss) from operations was  approximately $(113,000). The approximate net (loss) from operations for the three months to September 30, 2001  was approximately $(102,000).

- 16 -

----

Back to Contents

     *IMX Administrative Costs*:

     IMX’s central administrative costs reflect the resumption of corporate activity after the Effective Date of the Plan  of Reorganization. They were $96,000 during the third quarter of 2002. Administrative costs for the same period  during 2001 are not comparative to the 2002 numbers as the Company was operating a different business. IMX  operations for the quarter ended September 30, 2001 are not presented.

*Liquidity & Capital Resources*

     On September 30th, 2002, the Findstar’s consolidated financial condition included a working capital deficit,  excluding inter-company items, of about $(563,000) as compared to a deficit of approximately $(598,000) at June 30,  2002.

     At the end of September, TDMI had a working capital deficit of approximately $(1,319,000) as compared to a  deficit of about $(1,394,000) on June 30, 2002.

     IMX had a consolidated working capital deficit of approximately $(2,562,000) on September 30, 2002 as  compared to a deficit of approximately $(2,988,000) at June 30, 2002. During the quarter ended September 30, 2002,  the Company borrowed over $1 million from related parties and paid almost $400,000 in short term debt.

*Inflation*

     Inflation rates in the United States have not had a significant impact on operating results for the periods  presented.

*Cautionary Statement Regarding Forward-Looking Statements*

     Certain statements  contained in this item and elsewhere in this report regarding matters that are  not historical facts are forward-looking statements (as such term is defined  in the Private Securities Litigation Reform Act of 1995). Because such forward-looking  statements include risks and uncertainties, actual results may differ materially  from those expressed or implied by such forward-looking statements. All statements  that address operating performance, events or developments that management expects  or anticipates to incur in the future, including statements relating to sales  and earnings growth or statements expressing general optimism about future operating  results, are forward-looking statements. The forward-looking statements are  based on management’s current views and assumptions regarding future events  and operating performance. Many factors could cause actual results to differ  materially from estimates contained in management’s forward-looking statements.  The differences may be caused by a variety of factors, including but not limited  to adverse economic conditions, competitive pressures, inadequate capital, unexpected  costs, lower revenues and net incomes and forecasts, the possibility of fluctuation  and volatility of the Company’s operating results and condition, inability  to carry out marketing and sales plans, and loss of key executives, among other  things.

- 17 -

----

Back to Contents

**Item 4**     **Submission of Matters to a Vote of Security Holders**

     On November 4, 2002,  the Company held its annual shareholders meeting. All four directors nominated  by management, constituting the entire board of directors were elected and all  four proposals were adopted. The successful nominees were Stephen, Dean, Adrian  Stecyk, Dean Eaker, and Lyndon Chapman were unanimously elected. The 2002 Employee  Stock Option Plan, the change of the Company’s state of incorporation to  Delaware, the reduction of the conversion price of the Company’s Class  B Preferred Stock, and an increase in the authorized number of shares of Common  Stock to 100,000,000 were also adopted without a dissenting vote. 7,535,617  shares of Common Stock and 154,248 shares of Class B Preferred were voted for  the election of each director and in favor of each other item except for the  Class B revisions. With respect to that question, the holders of 7,535,617 shares  of Common Stock and 203,894 shares of Class B Preferred consented to the proposal.  No proxies were solicited or used in connection with the annual meeting.

**Item 5.**     **Election of Director**

     On October 4th, The company received Bruce Biegel’s resignation as an officer of TDMI and the Company and as  a Company Director. He has not been replaced. Mr. Biegel’s resignation was not the result of any dispute.

- 18 -

----

Back to Contents

**Part II. Other Information**

     Items 1, 3, 4, and 5 are omitted as they are either not applicable or have been included in Part I.

**Item 2, (a) Changes in the Rights of Security Holders**

     At the annual meeting, the holders of a majority of both classes approved changes in the provisions of the Class  B Preferred Stock. The changes accomplish all of the following:

|   | 1.     | The number of shares of Common Stock to be      issued upon conversion of each preferred share shall be doubled to 40 instead      of 20 as presently provided. This is accomplished by reducing the conversion      price to $2.00 per share of Common Stock. |
|--------|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |   |                                                                                                                                                                                                                                                           |
|   | 2.     | The present provision for further adjustments      of the conversion price, intended to protect against dilution upon the issuance      of shares of Common Stock at prices below the conversion price, is eliminated.                                         |
|   |   |                                                                                                                                                                                                                                                           |
|   | 3.     | The provision for payment or accumulation      of dividends at a rate of five (5%) percent per annum, payable in cash or      Common Stock, at the Company’s election, is eliminated.                                                                     |

**Item 2, (c) Recent Sales of Unregistered Securities**

     None

**Item 6. Exhibits and Reports on Form 8-K**

| (a)    |   | Exhibits |
|--------|--------|----------|
|   |

| **ExhibitNumber** |   | **Description**                                                                       |   |
|-------------------|--------|---------------------------------------------------------------------------------------|--------|
|                   |   |                                                                                  |   |
| 3.8               |   | Certificate of Incorporation      of Dialog Group, Inc.                               |   |
|              |   |                                                                                  |   |
| 3.9               |   | Agreement of Merger      between IMX Pharmaceuticals and Dialog Group Inc.            |   |
|              |   |                                                                                  |   |
| 3.10              |   | Delaware Certificate      of Merger between IMX Pharmaceuticals and Dialog Group Inc. |   |
|              |   |                                                                                  |   |
| 10.1              |   | IMX Pharmaceuticals,      Inc. 2002 Stock Option Plan.                                |   |

- 19 -

----

Back to Contents

| (b)    |   | Reports on Form 8-K                |
|--------|--------|------------------------------------|
|   |   |      None |

- 20 -

----

Back to Contents

**SIGNATURES**

     In accordance with the requirements of the Securities Exchange Act of 1934, the registrant has caused this  quarterly report on Form 10-QSB to be signed in its behalf by the undersigned thereunto duly authorized on the 14th  day of November 2002.

|   | **IMX PHARMACEUTICALS, INC** |
|--------|------------------------------|

|   |   |   |                                                                          |
|--------|--------|--------|-------------------------------------------------------------------------------|
|   | By:    |   | /s/ Adrian Stecyk           |
|   |   |   | Adrian Stecyk, President                                                      |
|   |

----